Earnings ·
Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, reporting a net loss of $122.7…
BEAMBeam Therapeutics Inc.
Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, reporting a net loss of $122.7 million, or $1.18 per share, compared to a net loss of $102.1 million in the prior year period. The company held $1.2 billion in cash and marketable securities as of June 30, 2026, with a runway expected to support operations into mid-2029. Clinically, Beam dosed the first patient in the global pivotal cohort for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) and completed dosing of all adult and adolescent patients in the Phase 1/2 BEACON trial for risto-cel in sickle cell disease. The company also received FDA clearance for the IND application for BEAM-304 in phenylketonuria (PKU). Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing.